MaxCyte, Inc. Revenue
MaxCyte, Inc. (MXCT) reported Revenue of $7.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-13
- MaxCyte, Inc. revenues for the quarter ending 2026-06-30 was $7.27M, a 14.53% decline year-over-year.
- MaxCyte, Inc. revenues for the quarter ending 2026-03-31 was $9.65M, a 7.11% decline year-over-year.
- MaxCyte, Inc. revenues for the quarter ending 2025-12-31 was $7.30M, a 16.02% decline year-over-year.
- MaxCyte, Inc. revenues for the quarter ending 2025-09-30 was $6.83M, a 16.35% decline year-over-year.
- MaxCyte, Inc. revenues for fiscal 2025 was $33.03M, a 14.50% decline from fiscal 2024.
- MaxCyte, Inc. revenues for fiscal 2024 was $38.63M, a 6.44% decline from fiscal 2023.
- MaxCyte, Inc. revenues for fiscal 2023 was $41.29M, a 6.72% decline from fiscal 2022.
- MaxCyte, Inc. revenues for fiscal 2022 was $44.26M, a 30.59% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.27M 10-Q · filed 2026-08-13 | $16.92M 10-Q · filed 2026-08-13 | $24.22M derived: sum of 3 quarters · filed 2026-08-13 | $31.05M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $9.65M 10-Q · filed 2026-05-13 | $16.95M derived: sum of 2 quarters · filed 2026-05-13 | $23.78M derived: sum of 3 quarters · filed 2026-05-13 | $32.29M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $14.13M derived: sum of 2 quarters · filed 2026-03-25 | $22.64M derived: sum of 3 quarters · filed 2026-08-13 | $33.03M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $6.83M 10-Q · filed 2025-11-13 | $15.34M derived: sum of 2 quarters · filed 2026-08-13 | $25.73M 10-Q · filed 2025-11-13 | $34.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $8.51M 10-Q · filed 2026-08-13 | $18.90M 10-Q · filed 2026-08-13 | $27.59M derived: sum of 3 quarters · filed 2026-08-13 | $35.75M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $10.39M 10-Q · filed 2026-05-13 | $19.08M derived: sum of 2 quarters · filed 2026-05-13 | $27.25M derived: sum of 3 quarters · filed 2026-05-13 | $37.68M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $16.86M derived: sum of 2 quarters · filed 2026-03-25 | $27.29M derived: sum of 3 quarters · filed 2026-03-25 | $38.63M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $8.16M 10-Q · filed 2025-11-13 | $18.59M derived: sum of 2 quarters · filed 2025-11-13 | $29.93M 10-Q · filed 2025-11-13 | $45.60M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $10.43M 10-Q · filed 2025-08-06 | $21.77M 10-Q · filed 2025-08-06 | $37.44M derived: sum of 3 quarters · filed 2025-08-06 | $45.44M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $11.34M 10-Q · filed 2025-05-08 | $27.01M derived: sum of 2 quarters · filed 2025-05-08 | $35.01M derived: sum of 3 quarters · filed 2025-05-08 | $44.05M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $23.67M derived: sum of 2 quarters · filed 2025-03-11 | $32.71M derived: sum of 3 quarters · filed 2025-03-11 | $41.29M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $8.00M 10-Q · filed 2024-11-06 | $8.00M 10-Q · filed 2023-11-08 | $17.05M derived: sum of 2 quarters · filed 2024-11-06 | $25.62M 10-Q · filed 2024-11-06 | $25.62M 10-Q · filed 2023-11-08 | $38.05M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $9.04M 10-Q · filed 2024-08-06 | $9.04M 10-Q · filed 2023-08-09 | $17.62M 10-Q · filed 2024-08-06 | $17.62M 10-Q · filed 2023-08-09 | $30.04M derived: sum of 3 quarters · filed 2024-08-06 | $40.68M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $8.58M 10-Q · filed 2024-05-07 | $8.58M 10-Q · filed 2023-05-10 | $21.00M derived: sum of 2 quarters · filed 2024-05-07 | $31.64M derived: sum of 3 quarters · filed 2024-05-07 | $41.25M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $12.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $23.07M derived: sum of 2 quarters · filed 2024-03-12 | $32.67M derived: sum of 3 quarters · filed 2024-03-12 | $44.26M 10-K · filed 2024-03-12 | $44.26M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $10.64M 10-Q · filed 2023-11-08 | $20.25M derived: sum of 2 quarters · filed 2023-11-08 | $31.84M 10-Q · filed 2023-11-08 | $41.99M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $9.61M 10-Q · filed 2023-08-09 | $21.20M 10-Q · filed 2023-08-09 | $31.35M derived: sum of 3 quarters · filed 2023-08-09 | $41.49M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $11.59M 10-Q · filed 2023-05-10 | $21.74M derived: sum of 2 quarters · filed 2023-05-10 | $31.88M derived: sum of 3 quarters · filed 2023-05-10 | $38.99M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $10.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $20.29M derived: sum of 2 quarters · filed 2023-03-15 | $27.40M derived: sum of 3 quarters · filed 2023-03-15 | $33.89M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $10.14M 10-Q · filed 2022-11-09 | $17.25M derived: sum of 2 quarters · filed 2022-11-09 | $23.74M 10-Q · filed 2022-11-09 | $32.26M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $7.11M 10-Q · filed 2022-08-10 | $13.60M 10-Q · filed 2022-08-10 | $22.12M derived: sum of 3 quarters · filed 2022-08-10 | $28.88M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $6.49M 10-Q · filed 2022-05-09 | $15.01M derived: sum of 2 quarters · filed 2022-05-09 | $21.77M derived: sum of 3 quarters · filed 2022-05-09 | $26.92M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $15.28M derived: sum of 2 quarters · filed 2022-03-22 | $20.43M derived: sum of 3 quarters · filed 2022-03-22 | $26.17M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $6.76M 10-Q · filed 2021-11-10 | $11.91M derived: sum of 2 quarters · filed 2021-11-10 | $17.65M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $5.15M 10-Q · filed 2021-09-13 | $10.89M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $21.62M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |